FULGENT GENETICS, INC. Recorded Unconditional Purchase Obligation, Due in Rolling Year Three
FULGENT GENETICS, INC. (FLGT) had Recorded Unconditional Purchase Obligation, Due in Rolling Year Three of $27.10 million as of 2023-09-30, per its 10-Q filed 2023-11-03.
Discontinued › Notes › Commitment and Contingencies
us-gaap:RecordedUnconditionalPurchaseObligationDueInRollingYearThree · last filed 2023-11-03
- 2023-09-30: Recorded Unconditional Purchase Obligation, Due in Rolling Year Three $27.10M.
- 2023-06-30: Recorded Unconditional Purchase Obligation, Due in Rolling Year Three $30.70M.
| Period end | Recorded Unconditional Purchase Obligation, Due in Rolling Year Three |
|---|---|
| 2023-09-30 | $27.10M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $30.70M 10-Q · filed 2023-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |